Navigation Links
Some patients with treatment-resistant colorectal cancers may have a new option
Date:6/2/2013

PHILADELPHIA A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs.

The MET gene is known to be amplified in about 10 percent of colorectal cancers, and is associated with worse prognosis.

The paper was also presented as part of an oral session at the 2013 American Society of Clinical Oncology Annual Meeting.

"Our studies provide evidence that colorectal cancer resistance to anti-EGFR therapies can be driven by MET gene amplification," said Alberto Bardelli, Ph.D., associate professor in the Department of Oncology at the University of Torino in Italy. "But what is more exciting is that we were able to detect these amplifications in the blood."

A subset of metastatic colorectal cancers responds to the anti-EGFR drugs cetuximab and panitumumab, but almost always develops resistance within several months of the initiation of therapy, according to Bardelli. Mutations in genes related to EGFR signaling, including KRAS, BRAF and NRAS, account for about 60 percent of the cases that develop resistance; the cause of resistance in tumors without these mutations is unknown.

"Unfortunately, patients whose tumors recur after anti-EGFR therapy are out of further options currently," said Bardelli. "The possibility that we can identify those who have MET amplification using a blood test is exciting because they might be treated with MET inhibitors."

Bardelli and his colleagues analyzed tumors from seven patients who developed resistance subsequent to anti-EGFR therapy, and identified three who did not have the previously known mutations. Using next-generation sequencing, they demonstrated amplification of the MET gene in these three tumor samples.

Blood samples collected at regular intervals during treatment with anti-EGFR therapy until relapse were available for two of the three patients. The researchers were able to detect MET amplification in the blood, and they demonstrated it occurred prior to relapse. The ability to detect MET amplification in blood provides a noninvasive, highly sensitive method for monitoring and predicting drug resistance and tumor recurrence, according to Bardelli.

Using "xenopatients" patient-derived, drug-resistant colorectal cancers grafted and grown in mice the researchers identified a novel, biologically distinct subset of tumors that were resistant to anti-EGFR drugs and did not have alterations in KRAS, BRAF or NRAS but carried MET amplification. The researchers further confirmed the overexpression of the MET gene and MET protein in these tumors using special techniques called fluorescent in situ hybridization and immunohistochemistry.

As a next step, the researchers tested the efficacy of the clinically approved MET inhibitor crizotinib in two xenopatients. According to Bardelli, a MET inhibitor in combination with an anti-EGFR drug caused maximum antitumor activity and sustained response in both xenopatients. He added that this provided proof of concept that MET inhibitors, alone or in combination with anti-EGFR therapies, offer novel therapeutic opportunities.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Therapy that heats and destroys bone tumors eases patients pain
2. Test helps target glioblastoma patients most likely to benefit from bevacizumab
3. Study finds glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life
4. Atlanta Hearing Institute Helps Atlanta Hearing Loss Patients Both Young and Old Dramatically Improve Quality of Life
5. Dr. Richard Shuldiner, First in California to Utilize New E-Scoop Glasses, Improve Way of Life for Low Vision Patients Suffering with Macular dDegeneration (ARMD)
6. Poorer Patients Often Less Happy With Knee Replacement
7. Obese Patients May Be More Prone to Doctor Shopping
8. Foundation Recognizes Patient Navigator Jackie Glenn of The Cancer Center at Lake Manassas for Work with Breast Cancer Patients
9. Researchers narrow the search for biomarkers of drug resistance in head and neck cancer patients
10. The Lap Band Center Announces Ways for Patients to Find Out How to Lose Weight Quickly and Efficiently
11. Educated Patients Decrease Fraud and Increase Quality of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud to ... Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment ... to address the limitations of fatigue monitoring technologies within the mining industry. Today ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... taught by healthcare management and evaluation leaders with decades of experience who remain ... in the United States healthcare system, there is a renewed demand for versatile, ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
(Date:1/23/2017)... ... 23, 2017 , ... Steviva Ingredients, makers of all-natural sweeteners ... National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... handling systems to complement our current rigorous food-safety management systems,” said Yishu Hou, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... partnership with the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia ... Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Jan. 20, 2017 ResMed (NYSE: RMD ), ... Winter Haven, Florida ) today announced they have agreed ... and 3B will be permitted to sell their existing products in ... one-time settlement payment to 3B to close the Florida ... include an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... Jan. 20, 2017  Faruqi & Faruqi, LLP, a leading ... or the "Company") (NASDAQ: KMPH ) of the ... certain officers and directors and underwriters of the Company,s April ... role of lead plaintiff. The lawsuit has been ... for Johnson County on behalf of ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: